Inozyme Pharmainc Stock Today
| INZY Stock | USD 4.40 0.01 0.23% |
Performance0 of 100
| Odds Of DistressOver 59
|
Inozyme PharmaInc is trading at 4.40 as of the 24th of April 2024; that is 0.23 percent up since the beginning of the trading day. The stock's open price was 4.39. Inozyme PharmaInc has over 59 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Inozyme PharmaInc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of July 2022 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of July 2020 | Category Healthcare | Classification Health Care |
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. The company has 61.77 M outstanding shares of which 2.58 M shares are currently shorted by private and institutional investors with about 3.61 trading days to cover. More on Inozyme PharmaInc
Moving together with Inozyme Stock
| 0.64 | BMY | Bristol Myers Squibb Earnings Call Tomorrow | PairCorr |
Moving against Inozyme Stock
| 0.49 | ELYM | Eliem Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Inozyme Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Inozyme PharmaInc's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Inozyme PharmaInc or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Chairman | Douglas Treco | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Inozyme PharmaInc report their recommendations after researching Inozyme PharmaInc's financial statements, talking to executives and customers, or listening in on Inozyme PharmaInc's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Inozyme PharmaInc. The Inozyme consensus assessment is calculated by taking the average forecast from all of the analysts covering Inozyme PharmaInc. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the measurements of operating efficiency obtained from Inozyme PharmaInc's historical financial statements, Inozyme PharmaInc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Inozyme PharmaInc is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Inozyme PharmaInc's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Inozyme PharmaInc's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inozyme PharmaInc's financial leverage. It provides some insight into what part of Inozyme PharmaInc's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Inozyme PharmaInc (INZY) is traded on NASDAQ Exchange in USA. It is located in 321 Summer Street, Boston, MA, United States, 02210 and employs 59 people. Inozyme PharmaInc is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 271.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Inozyme PharmaInc's market, we take the total number of its shares issued and multiply it by Inozyme PharmaInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Inozyme PharmaInc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.77 M outstanding shares of which 2.58 M shares are currently shorted by private and institutional investors with about 3.61 trading days to cover.
Inozyme PharmaInc currently holds about 151.48 M in cash with (70.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.77.
Check Inozyme PharmaInc Probability Of Bankruptcy
Ownership AllocationInozyme PharmaInc secures a total of 61.77 Million outstanding shares. The majority of Inozyme PharmaInc outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Inozyme PharmaInc to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Inozyme PharmaInc. Please pay attention to any change in the institutional holdings of Inozyme PharmaInc as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Inozyme Ownership Details
Inozyme Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Inozyme PharmaInc jumping above the current price in 90 days from now is over 95.22%. The Inozyme PharmaInc probability density function shows the probability of Inozyme PharmaInc stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.9041. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Inozyme PharmaInc will likely underperform. Additionally, inozyme PharmaInc has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Inozyme PharmaInc to move above the current price in 90 days from now is over 95.22 (This Inozyme PharmaInc probability density function shows the probability of Inozyme Stock to fall within a particular range of prices over 90 days) .
Inozyme Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Inozyme PharmaInc that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inozyme PharmaInc's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inozyme PharmaInc's value.| Instituion | Recorded On | Shares | |
| Sphera Funds Management Ltd. | 2023-12-31 | 1.6 M | |
| Samsara Biocapital, Llc | 2023-12-31 | 1.6 M | |
| Octagon Capital Advisors Lp | 2023-09-30 | 1.3 M | |
| Blue Owl Capital Holdings Lp | 2023-12-31 | 1.3 M | |
| Chi Advisors Llc | 2023-09-30 | 1.3 M | |
| Geode Capital Management, Llc | 2023-12-31 | 1 M | |
| Millennium Management Llc | 2023-12-31 | 911.5 K | |
| State Street Corporation | 2023-12-31 | 746.5 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 726.7 K | |
| Adage Capital Partners Gp Llc | 2023-12-31 | 5.5 M | |
| Pivotal Bioventure Partners Investment Advisor Llc | 2023-12-31 | 4.5 M |
Inozyme PharmaInc Historical Income Statement
Inozyme PharmaInc Income Statement is one of the three primary financial statements used for reporting Inozyme's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Inozyme PharmaInc revenue and expense. Inozyme PharmaInc Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Inozyme PharmaInc's Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 4.3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 19.8 K in 2024. View More FundamentalsInozyme Stock Against Markets
Picking the right benchmark for Inozyme PharmaInc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Inozyme PharmaInc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Inozyme PharmaInc is critical whether you are bullish or bearish towards Inozyme PharmaInc at a given time. Please also check how Inozyme PharmaInc's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Inozyme PharmaInc without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Inozyme PharmaInc Corporate Management
Elected by the shareholders, the Inozyme PharmaInc's board of directors comprises two types of representatives: Inozyme PharmaInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inozyme. The board's role is to monitor Inozyme PharmaInc's management team and ensure that shareholders' interests are well served. Inozyme PharmaInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inozyme PharmaInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henric Bjarke | VP COO | Profile | |
| MS MBA | CFO Officer | Profile | |
| Gayle Gironda | Senior Officer | Profile | |
| Soojin Kim | Senior Officer | Profile |
How to buy Inozyme Stock?
Before investing in Inozyme PharmaInc, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Inozyme PharmaInc. To buy Inozyme PharmaInc stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Inozyme PharmaInc. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Inozyme PharmaInc stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Inozyme PharmaInc stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Inozyme PharmaInc stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Inozyme PharmaInc, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.
Already Invested in Inozyme PharmaInc?
The danger of trading Inozyme PharmaInc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Inozyme PharmaInc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Inozyme PharmaInc. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Inozyme PharmaInc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Inozyme PharmaInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inozyme PharmaInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inozyme Pharmainc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inozyme Pharmainc Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme PharmaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.Note that the Inozyme PharmaInc information on this page should be used as a complementary analysis to other Inozyme PharmaInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Inozyme Stock analysis
When running Inozyme PharmaInc's price analysis, check to measure Inozyme PharmaInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme PharmaInc is operating at the current time. Most of Inozyme PharmaInc's value examination focuses on studying past and present price action to predict the probability of Inozyme PharmaInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme PharmaInc's price. Additionally, you may evaluate how the addition of Inozyme PharmaInc to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Inozyme PharmaInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inozyme PharmaInc. If investors know Inozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inozyme PharmaInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.37) | Return On Assets (0.28) | Return On Equity (0.55) |
The market value of Inozyme PharmaInc is measured differently than its book value, which is the value of Inozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Inozyme PharmaInc's value that differs from its market value or its book value, called intrinsic value, which is Inozyme PharmaInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inozyme PharmaInc's market value can be influenced by many factors that don't directly affect Inozyme PharmaInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inozyme PharmaInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inozyme PharmaInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inozyme PharmaInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.